Moving Science : What is the clinical value of Neurofilament light (Nfl) in MS Care today and in the future? 2/2

Join our continued discussion with Prof. Gavin Giovannoni and the panel as they delve deeper into current and future applications of NfL and other blood-based biomarkers.The panel explores key aspects of integrating NfL into medical practice, ranging from consistent assay methods for longitudinal data interpretation to accounting for comorbidities. They also address challenges when interpreting discrepancies and discuss access issues in different healthcare systems.Additionally, the experts examine the combination of NfL with other biomarkers such as GFAP and Neurofilament heavy chain in multivariate panels, assessing how these combinations can enhance diagnostic and prognostic value across different sub-populations, including pediatric patients and those with progressive courses of MS.Looking to the future, they imagine a world where people with MS can monitor their biomarker levels at home and explore the potential of blood-based biomarkers for screening and serial monitoring of individuals at risk for various neurological conditions.Immerse yourself in the recent developments and understand the emerging impact of fluid biomarkers in healthcare.